💊Ono Enters into Collaboration Agreement with Cyclenium Pharma, Inc

By Pharmaceutical

💊Ono Enters into Collaboration Agreement with Cyclenium Pharma, Inc.

Ono Pharmaceutical Co., Ltd. (Osaka Japan; President, Representative Director and CEO, Gyo Sagara; “Ono”) announced today that Ono and Cyclenium Pharma, Inc. (Montreal, Quebec,Canada; “Cyclenium”) signed a collaboration agreement, exploiting Cyclenium’s proprietary CMRTTM Technology and QUEST LibraryTM of next generation synthetic small-molecule macrocycles.

http://www.ono.co.jp/eng/news/pdf/sm_cn171212.pdf

More from tokioX :

  1. 💊Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma
  2. 💊Ono Enters into New Collaboration Agreement with Merus N.V.
  3. 💊Ono Enters into Exclusive License Agreement with Karyopharm to Develop and Commercialize Selinexor and KPT-8602, XPO1 Inhibitors  20171012
  4. 👾Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Advanced Non-squamous Non-small Cell Lung Cancer which Has Been Previously Treated with Platinum-based Therapy in Taiwan News Release
  5. Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Unresectable or Metastatic Melanoma in South Korea  20170919
  6. ono、Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
  7. Long-Term Analysis of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival in Patients with Relapsed Multiple Myeloma News Release 20170901